A generic version of hepatitis C virus (HCV) treatment sofosbuvir will soon hit the market in Morocco at a much lower cost than existing brand-name versions of the pill, Morocco World News reports.

The soon-to-be-released “100% Moroccan” drug—which contains the same active ingredients as Gilead Sciences’ brand-name Sovaldi treatment—was recently developed by the African pharmaceutical company Pharma Group 5 with help from Morocco’s Ministry of Health.

In developing the new generic drug, officials from Pharma Group 5 said it was working with the government to “improve the care of patients with hepatitis C, by enabling them to have access to treatment that was until now too expensive and missing on the Moroccan market.”

Today, Gilead’s version of sofosbuvir costs $84,000 for a standard 12-week course of treatment at market price. Moroccan officials have not yet named their price for the generic version of the drug, but are saying it will be “very reasonable.”